CABA: Cabaletta Bio Inc. Company Value to Net Income
The price chart for Cabaletta Bio, Inc. (CABA) shows a PE ratio of -1.70. Price action is driven by clinical trial results, with existing funds sufficient to complete current development programs. The stock's growth is tied to the efficacy of lupus therapy and the establishment of mass production for CARTA cells. Looking ahead, patenting the method will ensure global market reach and high profitability with low costs.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_CABA_-_Cabaletta-Bio-Inc._-_PE-Multiple "CABA: Cabaletta Bio, Inc. Business Payback Period 07/04/2022 - 11/10/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Cabaletta Bio, Inc (CABA)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
- earnings and market multiples details:
CABA - Net Profit|Projected Future Earnings Cabaletta Bio, Inc.|CABA - P/E Multiple|Future Price to Earnings Cabaletta Bio Inc.|CABA - PEG Multiple|EV/EBITDA Multiple Cabaletta Bio|CABA - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Cabaletta Bio, Inc.|CABA - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months cabalettabio.com|CABA - Net earnings per share growth this year|Projected earnings per share increase next year Cabaletta Bio, Inc.
Comprehensive company analysis:cabalettabio.com CABA
The P/E ratio measures the market value of a single unit of profit, determining the extent to which an investor is overpaying for future earnings. This metric reflects the balance between the current price and the fundamental profitability of the business. By analyzing the market P/E ratio of a company, one can identify zones of fair asset valuation. For Cabaletta Bio, Inc. (CABA), this indicator depends not on economic cycles, but on the prospects of clinical data in immunotherapy.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|AbCellera Bio - P/E Multiple|Tourmaline (TRML) - Price to Earnings Ratio|PGEN: P/E Multiple|pharming.com (PHAR) - P/E Multiple|NKTR (Nektar Therapeutics Inc.) - P/E Multiple|Price to Earnings Ratio UPB|P/E Multiple ZBIO|P/E Multiple Immunome Bio (IMNM)|Price to Earnings Ratio Gossamer Bio, Inc. GOSS|kalvista.com - Price to Earnings Ratio|Septerna - P/E Multiple|Market Cap to Earnings Pieris Pharma|SVRA (Savara Corp) - Price to Earnings Ratio|RIGL: Market Price to Net Income Ratio|Price to Earnings Ratio ANAB|ATXS (astriatx.com) - Market Price to Net Income Ratio|P/E Multiple ENGN|P/E Multiple RAPT Therapeutics Inc. (RAPT)|Aerovate Therapeutics - Price to Earnings Ratio|Company Value to Net Income ACRS|Kyverna Therapeutics - P/E Multiple|TLSA: Price to Earnings Ratio|VTYX: P/E Multiple|THTX - Business Payback Period|Price to Earnings Ratio Avalo Therapeutics Inc.|Market Cap to Earnings Eledon Pharmaceuticals, Inc ELDN|Price to Earnings Ratio AGEN (Agenus)|CLYM (climbbio.com) - Company Value to Net Income|P/E Multiple ZURA (Zura Bio)|Business Payback Period aTyr Pharma Inc (ATYR)|ADAG - Price to Earnings Ratio|IMA (ImageneBio Inc) - Price to Earnings Multiple|STTK: P/E Multiple|Price to Earnings Ratio Equillium|Price to Earnings Ratio CNTB|Immunic Inc (IMUX) - Business Payback Period|P/E Multiple ATRA|Price to Earnings Ratio inflarx.de IFRX|P/E Multiple XFOR (X4 Pharmaceuticals)|P/E Multiple Adicet Bio Inc. ACET|Celularity Corp - P/E Multiple|INMB: Price to Earnings Ratio|BRNS: P/E Multiple|Kezar Life Sciences Inc (KZR) - P/E Multiple|Price to Earnings Ratio SAB Biotherapeutics|akaritx.com - Market Cap to Net Income|P/E Multiple ENLV|QTTB (q32bio.com) - Company Value to Net Income|P/E Multiple GOVX (GeoVax Labs Inc)|P/E Multiple Edesa Biotech Corp EDSA|IBIO - Price to Earnings Ratio|Company Value to Net Income CARM (Carisma Therapeutics)|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Price to Earnings Ratio Bolt Biotherapeutics, Inc.|HCWB (HCW Biologics, Inc.) - P/E Multiple|P/E Multiple Aptevo|Price to Earnings Ratio AIM (AIM ImmunoTech Inc.)|ADTX (aditxt.com) - Company Value to Net Income|P/E Multiple GRI (GRI Bio)|Business Payback Period XORTX Therapeutics Inc (XRTX)|HIND - Price to Earnings Ratio|Revelation Biosciences Corp (REVB) - Price to Earnings Ratio|Indaptus Therapeutics (INDP) - Price to Earnings Ratio|Price to Earnings Ratio scinai.com|Price to Earnings Ratio CALI|P/E Multiple Affimed Therapeutics|Price to Earnings Ratio Allakos Inc. (ALLK)|hookipapharma.com - Price to Earnings Multiple|P/E Multiple IGMS (IGM Biosciences)|iteostherapeutics.com (ITOS) - Market Cap to Earnings|Ocean Biomedical - P/E Multiple|TC BioPharm (Holdings) Plc (TCBP) - Price to Earnings Ratio|THRD: P/E Multiple
